Victory Square Technologies Reports 2024 Results: Revenue Growth, Strategic Investments, and Portfolio Progress
Victory Square Technologies (OTC:VSQTF), a venture builder focused on high-growth technology companies, reported strong financial results for 2024, with adjusted revenue of $23.0 million, up from $17.6 million in 2023. GAAP revenue increased 39% year-over-year to $16.7 million, with gross margins of $6.4 million.
The company's key portfolio company, Hydreight Technologies (TSXV:NURS), in which Victory Square holds a 64% stake, achieved $16.0 million in GAAP revenue (up 39% YoY) and expanded its network to over 3,000 registered nurses and 200+ prescribing physicians across all U.S. states.
Victory Square also highlighted its 22.8% ownership in Insu Therapeutics, a biotech company developing an oral insulin tablet for diabetes care. The company completed strategic initiatives including the sale of BlockX for $1.7 million and maintains a strong balance sheet with $6.16 million in cash and marketable securities.
Victory Square Technologies (OTC:VSQTF), una venture builder specializzata in aziende tecnologiche ad alta crescita, ha riportato risultati finanziari solidi per il 2024, con un fatturato rettificato di 23,0 milioni di dollari, in aumento rispetto ai 17,6 milioni del 2023. Il fatturato GAAP è cresciuto del 39% su base annua, raggiungendo 16,7 milioni di dollari, con margini lordi pari a 6,4 milioni di dollari.
La principale società del portafoglio, Hydreight Technologies (TSXV:NURS), di cui Victory Square detiene il 64%, ha raggiunto un fatturato GAAP di 16,0 milioni di dollari (in crescita del 39% su base annua) e ha ampliato la sua rete a oltre 3.000 infermieri registrati e più di 200 medici prescrittori in tutti gli Stati Uniti.
Victory Square ha inoltre evidenziato la sua partecipazione del 22,8% in Insu Therapeutics, una società biotech che sviluppa una compressa orale di insulina per la cura del diabete. La società ha completato iniziative strategiche, inclusa la vendita di BlockX per 1,7 milioni di dollari, e mantiene un bilancio solido con 6,16 milioni di dollari in liquidità e titoli negoziabili.
Victory Square Technologies (OTC:VSQTF), una venture builder enfocada en empresas tecnológicas de alto crecimiento, reportó sólidos resultados financieros para 2024, con un ingreso ajustado de 23,0 millones de dólares, frente a los 17,6 millones de 2023. Los ingresos GAAP aumentaron un 39% interanual hasta 16,7 millones de dólares, con márgenes brutos de 6,4 millones de dólares.
La principal empresa del portafolio, Hydreight Technologies (TSXV:NURS), en la que Victory Square posee una participación del 64%, logró 16,0 millones de dólares en ingresos GAAP (un aumento del 39% interanual) y amplió su red a más de 3.000 enfermeros registrados y más de 200 médicos prescriptores en todos los estados de EE.UU.
Victory Square también destacó su 22,8% de propiedad en Insu Therapeutics, una empresa biotecnológica que desarrolla una tableta oral de insulina para el cuidado de la diabetes. La compañía completó iniciativas estratégicas, incluyendo la venta de BlockX por 1,7 millones de dólares, y mantiene un balance sólido con 6,16 millones de dólares en efectivo y valores negociables.
Victory Square Technologies (OTC:VSQTF)는 고성장 기술 기업에 집중하는 벤처 빌더로, 2024년 강력한 재무 실적을 보고했습니다. 조정 매출액은 2,300만 달러로 2023년의 1,760만 달러에서 증가했습니다. GAAP 매출은 전년 대비 39% 증가한 1,670만 달러를 기록했으며, 총 이익은 640만 달러였습니다.
Victory Square가 64% 지분을 보유한 주요 포트폴리오 회사인 Hydreight Technologies (TSXV:NURS)는 1,600만 달러의 GAAP 매출(전년 대비 39% 증가)을 달성했으며, 미국 전역에 걸쳐 3,000명 이상의 등록 간호사와 200명 이상의 처방 의사 네트워크를 확장했습니다.
Victory Square는 또한 당뇨병 치료를 위한 경구용 인슐린 정제를 개발하는 바이오텍 회사인 Insu Therapeutics에 대한 22.8% 지분을 강조했습니다. 회사는 170만 달러에 BlockX를 매각하는 등 전략적 이니셔티브를 완료했으며, 616만 달러의 현금 및 시장성 증권을 보유해 견실한 재무 상태를 유지하고 있습니다.
Victory Square Technologies (OTC:VSQTF), un incubateur d'entreprises axé sur les sociétés technologiques à forte croissance, a annoncé de solides résultats financiers pour 2024, avec un chiffre d'affaires ajusté de 23,0 millions de dollars, en hausse par rapport à 17,6 millions en 2023. Le chiffre d'affaires selon les normes GAAP a augmenté de 39 % en glissement annuel pour atteindre 16,7 millions de dollars, avec une marge brute de 6,4 millions de dollars.
La principale société du portefeuille, Hydreight Technologies (TSXV:NURS), dans laquelle Victory Square détient une participation de 64 %, a réalisé un chiffre d'affaires GAAP de 16,0 millions de dollars (en hausse de 39 % en glissement annuel) et a étendu son réseau à plus de 3 000 infirmières enregistrées et plus de 200 médecins prescripteurs dans tous les États-Unis.
Victory Square a également mis en avant sa participation de 22,8 % dans Insu Therapeutics, une société biotechnologique développant un comprimé d'insuline oral pour le traitement du diabète. La société a mené à bien des initiatives stratégiques, dont la vente de BlockX pour 1,7 million de dollars, et maintient un bilan solide avec 6,16 millions de dollars en liquidités et titres négociables.
Victory Square Technologies (OTC:VSQTF), ein Venture Builder mit Fokus auf wachstumsstarke Technologieunternehmen, meldete starke Finanzergebnisse für 2024 mit einem bereinigten Umsatz von 23,0 Millionen US-Dollar, gegenüber 17,6 Millionen US-Dollar im Jahr 2023. Der GAAP-Umsatz stieg im Jahresvergleich um 39 % auf 16,7 Millionen US-Dollar, mit Bruttomargen von 6,4 Millionen US-Dollar.
Das wichtigste Portfoliounternehmen des Unternehmens, Hydreight Technologies (TSXV:NURS), an dem Victory Square 64 % hält, erzielte 16,0 Millionen US-Dollar GAAP-Umsatz (ein Plus von 39 % gegenüber dem Vorjahr) und erweiterte sein Netzwerk auf über 3.000 registrierte Pflegekräfte und mehr als 200 verschreibende Ärzte in allen US-Bundesstaaten.
Victory Square hob außerdem seine 22,8%ige Beteiligung an Insu Therapeutics hervor, einem Biotech-Unternehmen, das eine orale Insulintablette zur Diabetesbehandlung entwickelt. Das Unternehmen schloss strategische Initiativen ab, darunter den Verkauf von BlockX für 1,7 Millionen US-Dollar, und verfügt über eine starke Bilanz mit 6,16 Millionen US-Dollar in bar und marktfähigen Wertpapieren.
- Adjusted revenue grew to $23.0 million in 2024 from $17.6 million in 2023
- GAAP revenue increased 39% year-over-year to $16.7 million
- Gross margin improved to $6.4 million from $5.5 million in 2023
- Strong balance sheet with $6.16 million in cash and marketable securities
- Successfully monetized BlockX asset for $1.7 million in listed shares
- Portfolio company Hydreight achieved 39% YoY revenue growth to $16.0 million
- Hydreight reached positive net income and adjusted EBITDA of $163,000 in Q1 2025
- Cost of Goods Sold increased significantly to $10.4 million from $6.6 million in 2023
- Insu Therapeutics' first-in-human trials not planned until 2026
Victory Square Reports
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - Victory Square Technologies Inc. (CSE: VST) (OTC Pink: VSQTF) ("Victory Square" or the "Company"), a venture builder that invests in and develops high-growth technology companies, is pleased to share a summary of key milestones and audited financial highlights for the year ended December 31, 2024.
The Company delivered a year of meaningful progress across its portfolio, highlighted by record financial performance, strategic asset monetization, and accelerating growth in its healthcare investments. These results position Victory Square for continued execution, strong momentum and a clear vision for long-term shareholder value creation in 2025 and beyond.
2024 Financial and Strategic Highlights
Adjusted Revenue: Victory Square generated approximately
$23.0 million in adjusted revenue in 2024, up from$17.6 million in 2023.GAAP Revenue:
$16.7 million in 2024, compared to$12.1 million in the prior year, representing a39% year-over-year increase.Cost of Goods Sold (COGS):
$10.4 million in 2024, compared to$6.6 million in 2023.Gross Margin:
$6.4 million in 2024, compared to$5.5 million in 2023.Asset Monetization: Completed the sale of BlockX to Edge Total Intelligence Inc. (TSXV: CTRL) in Q3 2024 for
$1.7 million in listed shares.Strong Balance Sheet: including
$6.16 million in cash and marketable securities, providing ample resources to fuel future growth and pursue strategic initiatives.
Please see SEDAR+ for the Company's condensed consolidated audited financial statements and MD&A for audited annual consolidated financial statements for the year ended December 31, 2024.
Hydreight Technologies: A Scalable Health Platform
Hydreight Technologies Inc. (TSXV: NURS), a digital health company incubated by Victory Square, continued to scale its mobile wellness and telehealth platform across the U.S., achieving:
$16.0 million in GAAP revenue for FY2024, up39% YoY, and$22.3 million in adjusted revenue, up31% YoY.Q1 2025 revenue of
$6.53 million , up34% YoY, with positive net income and adjusted EBITDA of$163,000. National recognition including rankings on the Deloitte Technology Fast 50 (Canada, #9), Fast 500 (North America, #56), and Ranked #13 on the Americas' Fastest Growing Companies 2025 list.
Expanded National Network: Hydreight's platform now supports a network of over 3,000 registered nurses and 200+ prescribing physicians, serving patients across all 50 U.S. states. In addition to its core clinical provider base, Hydreight powers 400+ direct-to-consumer (D2C) healthcare brands and multiple white-label wellness partners, enabled by its scalable, plug-and-play infrastructure.
On December 31, 2024, Victory Square held a
Health Innovation: Strategic Initiatives in 2024-25
Victory Square deepened its commitment to digital health through several key initiatives:
VSDHOne Platform: A national, plug-and-play infrastructure for launching compliant direct-to-consumer healthcare brands across all 50 U.S. states.
$10M Health Accelerator: Designed to incubate and invest in digital health startups focused on areas like biomarker testing, peptides, tele-pharmacy, and longevity.Pet Health: Victory Square is evaluating the growing pet wellness sector, building on prior virtual care solutions for animals.
Insu Therapeutics: Advancing Oral Insulin for Diabetes Care
Another promising digital health holding in Victory Square's portfolio is Insu Therapeutics Inc., a biotechnology company developing a non-invasive, oral insulin tablet for people living with diabetes. Victory Square holds approximately
Insu's tablet uses a buccal delivery system—absorbing insulin through the inner cheek-bypassing the digestive tract and mimicking the body's natural insulin absorption via the liver. Preclinical trials have demonstrated insulin uptake comparable to injections, with prolonged glucose control and improved liver targeting.
This innovation addresses a global health need. According to the International Diabetes Federation, over 500 million people worldwide are living with diabetes as of 2021, with the number expected to rise to 783 million by 2045. The global diabetes therapeutics market is projected to reach USD
Key highlights from Insu's development roadmap:
Filed U.S. and international patents covering its novel tablet formulation and delivery polymers.
Pursuing an FDA 505(b)(2) regulatory pathway, aiming to reduce development costs and timelines.
Planning first-in-human trials in 2026, following preclinical success.
Exploring domestic insulin tablet manufacturing to increase supply chain resilience.
Insu is led by a multidisciplinary team:
Dr. Anubhav Pratap-Singh (CEO & Co-Inventor): UBC Professor with 100+ publications and 7+ patents.
Ammad Shorbaji (COO): Former senior executive at Sanofi with 25 years of regulatory and commercial experience.
Dr. Tom Elliott (Medical Director): A leading Canadian endocrinologist with extensive clinical and academic credentials.
Insu's work has garnered national and international media attention, with coverage from CBC, Global News, and other major outlets. This growing visibility supports early awareness as the company moves toward commercialization.
Victory Square believes Insu Therapeutics represents both a strong commercial opportunity and a mission-aligned investment aimed at improving global health outcomes. The Company continues to support Insu through its next phase of growth and development.
Outlook for 2025 and Beyond
Victory Square enters 2025 with a strengthened balance sheet, a growing healthcare ecosystem, and a pipeline of high-potential assets. The Company's focus for 2025 includes:
Scaling adoption of VSDHOne and expanding digital health verticals.
Supporting growth of Hydreight and advancing Insu's clinical roadmap.
Monetizing additional assets where appropriate.
Continuing investment in biotech, health, and scalable technology platforms.
"2024 was a pivotal year for Victory Square," said Shafin Diamond Tejani, CEO. "We strengthened our balance sheet, scaled promising platforms, and unlocked value across the portfolio. We're committed to supporting innovation and creating long-term value for our shareholders in 2025 and beyond."
Victory Square thanks its shareholders for their continued support and looks forward to sharing additional updates throughout the year.
Sign up to VST's official newsletter at www.VictorySquare.com/newsletter.
On behalf of the Board of Directors
"Shafin Diamond Tejani"
Director and Chief Executive Officer
Victory Square Technologies Inc.
www.victorysquare.com
For further information about Victory Square, please contact:
Investor Relations Contact — Abbey Vogt
Email: ir@victorysquare.com
Telephone: 604 283-9166
Peter Smyrniotis — Director
Telephone: 604 283-9166
ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square is a Venture Builder that provides investors a liquid way to invest in early-stage technology companies without buying a venture fund that requires accredited investor status or multi-year commitments.
- A diverse portfolio of 25+ innovative companies from around the world (founders come from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America)
- Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain/Web3, Virtual & Augmented Reality (VR/AR), Gaming, Climate Tech
- Owner-operated (approx.
15% Management Ownership)
Business Model:
The Victory Square business model is to buy, build and invest in early stage tech companies. We spend upwards of 48 months with those companies until they're ready to spin-off or stand on their own. There are a couple of unique elements to our business model…
- We have unparalleled access to startups through our internal incubator and International network with over 250+ founders, investors, tech accelerators and venture capital firms from more than 60 countries.
- Second, our management team and advisors are actively involved in our investments from incubation through monetization, providing them with financial, operational, and strategic support to scale globally.
- We drive value by monetizing investments and reinvesting the gains in new innovations. The strategy was to build a self-sustaining business.
VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTC Pink (VSQTF).
For more information, please visit www.victorysquare.com.
Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words "believes," "may," "plans," "will," "anticipates," "intends," "could," "estimates," "expects," "forecasts," "projects" and similar expressions, and the negative of such expressions. All statements other than statements of historical facts contained in this news release are forward looking statements. Forward-looking information in this news release includes, without limitation, statements regarding the future plans and objectives of the Company, execution of business strategy, future performance and future growth, business prospects, synergies and opportunities of the Company and its related subsidiaries, and other factors beyond the Company's control.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company's actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made, including, but not limited to the Company being able to capitalize on the acquired assets, the ability of acquired assets to maintain its value as presently contemplated, the synergies of the acquired assets with the Company's operations, and such other assumptions presented in the Company's disclosure record. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information herein is qualified in its entirety by this cautionary statement, and GameOn disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Use of Non-GAAP Financial Measures
This release contains references to non-GAAP financial measures Adjusted Revenue and Adjusted EBITDA. The Company defines Adjusted Revenue as gross cash income before adjustments for the deferred portion of business partner setup, license, and sponsorship fees and gross and accrued receipts from blockchain grant funding. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs and share-based payments expense, and (iii) gains/losses that are not reflective of ongoing operating performance including inventory impairment. The Company believes that the measure provides useful information to its shareholders and investors in understanding the Company's 2023 operating cash flow and may assist in the evaluation of the Company's business relative to that of its peers more accurately than GAAP financial measures alone. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of other metrics presented in accordance with GAAP.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257416
FAQ
What were Victory Square Technologies' (VSQTF) key financial results for 2024?
How did Hydreight Technologies perform in Victory Square's portfolio for 2024?
What is Victory Square's ownership stake in Insu Therapeutics and its development timeline?
How much cash and marketable securities does Victory Square (VSQTF) have on its balance sheet?
What strategic assets did Victory Square monetize in 2024?
